Physician profile
Shyamsunder Subramanian
NPI 1871588731
$1,497,094.45
in general payments reported to CMS, 2019-2025
44 companies · $301K in 2025
The $301K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297K · 2020: $113K · 2021: $146K · 2022: $150K · 2023: $335K · 2024: $155K · 2025: $301K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $626K · Travel and Lodging: $67K · Consulting Fee: $65K · Food and Beverage: $22K · Honoraria: $12K · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $626,304.20 |
| Travel and Lodging | $66,585.80 |
| Consulting Fee | $64,645.75 |
| Food and Beverage | $21,777.20 |
| Honoraria | $11,500.00 |
| Education | $467.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $433,867.27 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $355,529.40 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $164,490.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $121,732.85 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107,783.75 | 2019-2025 | Ofev, Jascayd |
| Teva Pharmaceuticals USA, INC. | $68,592.40 | 2019-2022 | |
| Lilly USA, LLC | $68,107.23 | 2025 | Zepbound |
| Genentech USA, INC. | $53,527.47 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $46,740.14 | 2019-2024 | Yupelri, Yupelri |
| Amgen INC. | $20,779.45 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $12,363.72 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $9,655.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $7,846.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $7,528.78 | 2019 | |
| Advanced Respiratory, INC | $5,963.96 | 2019-2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $5,073.26 | 2023 | Joenja |
| Astrazeneca Uk Limited | $1,556.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Zoll Medical Corporation | $1,050.00 | 2023 | |
| Hill-Rom Company, INC | $957.93 | 2019-2021 | |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Baxter Healthcare | $393.87 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Monarch Airway Clearance System |
| Inspire Medical Systems, INC. | $373.42 | 2023-2025 | Inspire |
| Mayne Pharma Commercial LLC | $267.32 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $187.18 | 2025 | |
| United Therapeutics Corporation | $160.93 | 2024-2025 | Tyvaso, Tyvaso |
| Axsome Therapeutics, INC. | $115.19 | 2025 | Sunosi |
| Astellas Pharma US INC | $93.37 | 2019-2021 | |
| Electromed, INC. | $93.22 | 2019-2025 | Smartvest |
| Philips North America LLC | $70.57 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
| Genentech, INC. | $47.33 | 2019-2020 | |
| Insmed, INC. | $41.22 | 2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $39.80 | 2020 | |
| Viatris Specialty LLC | $36.70 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $35.84 | 2019-2021 | |
| Pfizer INC. | $34.85 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $33.11 | 2020-2024 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $32.92 | 2025 | |
| Allergan, INC. | $22.86 | 2020 | |
| Grifols USA, LLC | $15.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.91 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.09 | 2020 | |
| Circassia INC. | $13.02 | 2020 | |
| Shire North American Group INC | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyamsunder Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.